Pharmacokinetics and antitumor activity of a bivalent disulfide- stabilized Fv immunotoxin with improved antigen binding to erbB2

Cancer Research

Volumn 59, Issue 16, 1999, Pages 4018-4022

  Bera, Tapan K ^a   Viner, Jaye ^a   Brinkmann, Elisabeth ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN FRAGMENT; IMMUNOTOXIN;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CYTOTOXICITY; DISULFIDE BOND; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; EXOTOXINS; FEMALE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTOXINS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; RECEPTOR, ERBB-2; SULFIDES;

EID: 0033567023     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Vitetta, E. S., Fulton, R. J., May, R. D., Till M., and Uhr, J. M. Redesigning nature's poisons to create anti-tumor reagents. Science (Washington DC), 238: 1098-1104, 1987.
2. Mulshine, J. L., Magnani, S. L., and Linnoila, R. I. Applications of monoclonal antibodies in treatment of solid tumors. In: V. De Vita, S. Hellman, and S. Rosenberg (eds.), Principles of Biotherapy. Philadelphia: J. B. Lippincott, 1991.
3. Pastan, I., Pai, L. H., Brinkmann, U., and FitzGerald, D. J. Recombinant toxins: new therapeutic agents for cancer. Ann. N. Y. Acad. Sci., 758: 345-354, 1995.
4. Brinkmann, U., and Pastan, I. Recombinant immunotoxins: from basic research to cancer therapy. Methods: A Companion to Methods Enzymol. 8: 143-156, 1995.
5. Pastan, I., and FitzGerald, D. Recombinant toxins for cancer treatment. Science (Washington DC), 254: 1173-1177, 1991.
6. Hwang, J., FitzGerald, D. J., Adhya, S., and Pastan, I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell, 48: 129-136, 1987.
7. Brinkmann, U., Pai, L. H., FitzGerald, D. J., and Pastan, I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment (dsFv). Proc. Natl. Acad. Sci. USA, 88: 8616-8620, 1991.
8. Pai, L. H., Batra, J. K., FitzGerald, D. J., Willingham, M. C., and Pastan, I. Antitumor activities of immunotoxin made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA, 88: 3358-3362, 1991.
9. Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., Riordan, G. S., and Whitlow, M. Single-chain antigen-binding proteins. Science (Washington DC), 242: 423-426, 1988.
10. Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., Crea, R., and Oppermann, H. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA, 16: 5879-5883, 1988.
11. Bera, T. K., Onda, M., Brinkmann, U., and Pastan, I. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2. J. Mol. Biol., 281: 475-483, 1998.
12. King, C. R., Kraus, M. H., and Aaronson, S. A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (Washington DC), 229: 974-976, 1985.
13. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Strart, S. G., Udove, J., Ullrinch, A., and Press, M. F. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
14. Yokota, J., Yamamoto, T., Toyoshima, K., Sugimura, T., Terada, M., Battifora, H., and Cline, M. J. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet, ii: 765-767, 1986.
15. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segato, O., King, C. R., and Aaronson, S. A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (Washington DC), 237: 178-182, 1989.
16. Hudziak, R. M., Schlessinger, J., and Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH/ 3T3 cells. Proc. Natl. Acad. Sci. USA, 84: 7159-7163, 1987.
17. Buchner, J., Pastan, I., and Brinkmann, U. A method to increase the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem., 205: 263-270, 1992.
18. Reiter, Y., Pai, L. H., Brinkmann, U., Wang, Q-C., and Pastan, I. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res., 54: 2714-2718, 1994.
19. Reiter, Y., Brinkmann, U., Jung, S-H., Lee, B., Kasprzyk, P. G., King, C. R., and Pastan, I. Improved binding and anti tumor activity of a recombinant anti-erbB2 immunotoxin by disulfide-stabilization of the Fv fragment. J. Biol. Chem., 269: 18327-18331, 1994.
20. Hynes, N. E., Gerber, H. A., Saure, S., and Groner, B. Overexpression of the c-erbB-2 protein in human breast tumor cell lines. J. Cell. Biochem., 39: 167-173, 1989.
21. Daly, J. M., Jannot, C. B., Beerli, R. R., Graus-porta, D., Maurer, F. G., and Hynes, N. E. Neu differentiation factor induces erbB2 down-regulation and apoptosis of erbB2-overexpressing breast tumor cells. Cancer Res., 57: 3804-3811, 1997.
22. Kreitman, R., and Pastan, I. Accumulation of a recombinant immunotoxin in a tumor in vivo: less than 1000 molecules per cell is sufficient for complete responses. Cancer Res., 58: 968-975, 1998.
23. 486 IL-2 in animal models. Cancer Chemother. Pharmacol., 26: 409-414, 1990.
24. Saga, T., Neumann, R. D., Heya, T., Sato, J., Kinuya, S., Le, N., Paik C. H., and Weinstein, J. N. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc. Natl. Acad Sci. USA, 92: 8999-9003, 1995.